Abstract:Vaikunthavasan Thiruchenthooran, 1 Marta &Sacutewitalska, 2 Gabriela Maciejewska, 3, 4 Anna Palko-&Lstrokabuz, 5 Lorena Bonilla-Vidal, 6, 7 Joanna Wietrzyk, 2 Eliana B Souto, 8 Elena Sánchez-López, 6, 7, &ast Anna Gliszczy&nacuteska 1, &ast 1 Department of Food Chemistry and Biocatalysis, Wroc&lstrokaw University of Environmental and Life Sciences, Wroc&lstrokaw, Poland; 2 Department of Experimental Oncology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroc&lstrokaw, Poland; 3 Central Laboratory of the Instrumental Analysis, Wroc&lstrokaw University of Technology, Wroc&lstrokaw, Poland; 4 Omics Research Center, Wroc&lstrokaw Medical University, Wroc&lstrokaw, Poland; 5 Department of Biophysics and Neuroscience, Wroc&lstrokaw Medical University, Wroc&lstrokaw, Poland; 6 Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, University of Barcelona, Barcelona, 08028, Spain; 7 Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, Barcelona, 08028, Spain; 8 UCD School of Chemical and Bioprocess Engineering, University College Dublin, Dublin, D04 V1W8, Ireland &astThese authors contributed equally to this work Correspondence: Anna Gliszczy&nacuteska; Elena Sánchez-López, Email ; Purpose: It is well known that the nonsteroidal anti-inflammatory drug (NSAID) indomethacin (IND) exhibits significant anticancer potential reported not only by in vitro and in vivo studies, but also in clinical trials. Despite promising results, IND is not widely used as an adjunctive agent in cancer therapy due to the occurrence of several gastrointestinal side effects, primarily after oral administration. Therefore, this study aimed to develop a nanosystem with reduced toxicity and risk of side effects for the delivery of IND for cancer treatment. Methods: IND was encapsulated in nanostructured lipid carriers (NLC) in the form of a phospholipid conjugate, where a covalent bond exists between the drug and phosphatidylcholine skeleton. For this purpose, seven new hybrid molecules were synthesized, and subsequently evaluated as anticancer agents in an in vitro model against selected cancer cell lines. Results: Biological studies demonstrated that the synthesized conjugates possessed excellent antiproliferative effects, exhibiting a 2.7-fold to even 100-fold higher activity against selected cancer cells, while remaining non-toxic to healthy cells. Based on biological studies and molecular calculations, heterosubstituted phosphatidylcholine containing IND and oleic acid (IND-OA-PC) in the sn -1 and sn -2 positions, respectively, was identified as the most potent molecule. Subsequently, IND-OA-PC was encapsulated in nanostructured lipid carriers (IND-OA-PC-NLC). The results revealed that IND-OA-PC-NLC has a spherical shape with an average diameter of 155 nm and a negatively charged surface (– 17.4 ± 0.49 mV). In this study, it was proven that the encapsulated conjugate of indomethacin with PC exhibits high activity against triple-negative (TNBC, Her2-, PR-, and ER-) breast cancer cells MDA-MB-468. While free IND was active at a concentration of 270.5 μM, in the form of the phospholipid conjugate (IND-OA-PC), it inhibited the growth of cancer cells at 67.5 μM and after conjugate encapsulation (IND-OA-PC-NLC) it was effective at only 10.3 μM. Conclusion: Our study revealed that the conjugation of NSAID with phosphatidylcholine and its combination with nanotechnology techniques create opportunities to repurpose well-known drugs from this group for new therapeutic applications. Keywords: indomethacin, phospholipid conjugates, long-chain fatty acids, nanostructured lipid carrier, nanoparticles, anticancer properties According to the report of the World Health Organization (WHO), cancer caused nearly 10 million deaths worldwide in 2020. 1 This staggering toll not only reflects the magnitude of human suffering, but also underscores the urgency to pursue effective interventions. Commonly used conventional therapies, such as chemotherapy and radiation, are often insufficient for tumor treatment. Moreover, neoadjuvant chemotherapy does not improve the patient's quality of life or guarantee overall survival compared to chemoradiotherapy. 2 Even adjuvant chemotherapy combinations do not provide the expected magnitude of survival benefit and often lead to more serious side effects than chemoradiotherapy alone. 3 Despite significant progress i -Abstract Truncated-

Indomethacin Induces Spermidine/Spermine-N1-Acetyltransferase-1 via the Nucleolin-CDK1 Axis and Synergizes with the Polyamine Oxidase Inhibitor Methoctramine in Lung Cancer Cells

Nicotinamide N -methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization

S-adenosylmethionine Inhibits Non-Small Cell Lung Cancer and Enhances Chemosensitivity by Targeting the P62/NF-κB Axis and Regulating Autophagy and Oxidative Stress

NSAID Indomethacin Enhanced Cytostatic Effect of Cis-Platinum of the Proliferation of Prostaglandin Producing and Non-Producing Cancers in Cell Line

Synergistic Effect of Indomethacin and NGX6 on Proliferation and Invasion by Human Colorectal Cancer Cells Through Modulation of the Wnt/β-catenin Signaling Pathway

NSAID targets SIRT3 to trigger mitochondrial dysfunction and gastric cancer cell death

mTOR Signaling is Involved in Indomethacin and Nimesulide Suppression of Colorectal Cancer Cell Growth via a COX-2 Independent Pathway

Multifunctional Indomethacin Conjugates for the Development of Nanosystems Targeting Cancer Treatment

Indomethacin Induces Apoptosis in the Ec109 Esophageal Cancer Cell Line by Releasing Second Mitochondria-Derived Activator of Caspase and Activating Caspase-3

Inducible Nitric Oxide Inhibitor Enhances the Anti-Tumor Effect of Cisplatin on CNE-2 Cells by Inducing Cell Apoptosis.

Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy

Inhaled Indomethacin-Loaded Liposomes as Potential Therapeutics against Non-Small Cell Lung Cancer (NSCLC)

Abstract 6333: Repurposing NSAIDs for Chemo-Immunotherapy: Mechanisms Beyond COX Inhibition

[Effects of Indomethacin on Proliferation and Senescence of Leukemia Cells]

Preliminary proteomic analysis of indomethacin's effect on tumor transplanted with colorectal cancer cell in nude mice.

Abstract 1937: Inhibition of a novel cancer target, PDE10, suppresses Wnt/β-catenin signaling and colon tumorigenesis: Benefits from combining with ornithine decarboxylase inhibitors

Histone deacetylase inhibition overcomes drug resistance through a miRNA-dependent mechanism

Non-steroidal anti-inflammatory drugs decrease E2F1 expression and inhibit cell growth in ovarian cancer cells

Effects of Indomethacin on the Growth and Metastasis of Hepatocellular Carcinoma

The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity

Ido Downregulation Induces Sensitivity To Pemetrexed, Gemcitabine, Fk866, And Methoxyamine In Human Cancer Cells